Page 43 - Read Online

Orekhov et al. Vessel Plus 2019;3:3 I http://dx.doi.org/10.20517/2574-1209.2018.80 Page 13 of 14

cardiovascular disease. Curr Pharm Des 2011;17:27-37.
41. Ivanova EA, Bobryshev YV, Orekhov AN. LDL electronegativity index: a potential novel index for predicting cardiovascular disease.
Vasc Health Risk Manag 2015;11:525-32.
42. Akyol S, Lu J, Akyol O, Akcay F, Armutcu F, et al. The role of electronegative low-density lipoprotein in cardiovascular diseases and its
therapeutic implications. Trends Cardiovasc Med 2017;27:239-46.
43. Sobenin IA, Salonen JT, Zhelankin AV, Melnichenko AA, Kaikkonen J, et al. Low density lipoprotein-containing circulating immune
complexes: role in atherosclerosis and diagnostic value. Biomed Res Int 2014;2014:205697.
44. Sobenin IA, Karagodin VP, Melnichenko AC, Bobryshev YV, Orekhov AN. Diagnostic and prognostic value of low density lipoprotein-
containing circulating immune complexes in atherosclerosis. J Clin Immunol 2013;33:489-95.
45. Orekhov AN, Kalenich OS, Tertov VV, Novikov ID. Lipoprotein immune complexes as markers of atherosclerosis. Int J Tissue React
1991;13:233-6.
46. Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, Wilson PF, et al. Immune complexes containing modified lipoproteins are related to
the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007;190:359-69.
47. Lopes-Virella MF, Hunt KJ, Baker NL, Virella G; VADT Group of Investigators. High levels of AGE-LDL, and of IgG antibodies
reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in
patients with type 2 diabetes. J Diabetes Complications 2016;30:693-9.
48. Orekhov AN, Bobryshev YV, Sobenin IA, Melnichenko AA, Chistiakov DA. Modified low density lipoprotein and lipoprotein-
containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular
disease. Int J Mol Sci 2014;15:12807-41.
49. Sobenin IA, Orekhova VA, Melnichenko AА, Bobryshev YV, Orekhov AN. Low density lipoprotein-containing circulating immune
complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters. Int J Cardiol
2013;166:747-8.
50. Leopold JA. Antioxidants and coronary artery disease: from pathophysiology to preventive therapy. Coron Artery Dis 2015;26:176-83.
51. American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, Brands M, Carnethon M, et al. Diet and lifestyle
recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation
2006;114:82-96.
52. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence,
etiology, and therapeutic challenges. Curr Atheroscler Rep 2012;14:1-10.
53. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, et al. Efficacy and safety of
LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
Lancet 2015;385:1397-405.
54. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death
with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
55. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-
risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
56. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, et al. Primary prevention of acute coronary events with lovastatin in men and
women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
JAMA 1998;279:1615-22.
57. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. The effect of pravastatin on coronary events after myocardial
infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9.
58. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. Prevention of coronary heart disease with pravastatin in men with
hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
59. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis
of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
60. Chen Z, Peto R, Collins R, MacMahon S, Lu J, et al. Serum cholesterol concentration and coronary heart disease in population with low
cholesterol concentrations. BMJ 1991;303:276-82.
61. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, et al. Effect of pravastatin on coronary disease events in subgroups defined
by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-900.
62. Kijani S, Vázquez AM, Levin M, Borén J, Fogelstrand P. Intimal hyperplasia induced by vascular intervention causes lipoprotein
retention and accelerated atherosclerosis. Physiol Rep 2017; doi: 10.14814/phy2.13334.
63. Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the
pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol 2016;27:473-83.
64. Chistiakov DA, Myasoedova VA, Revin VV, Orekhov AN, Bobryshev YV. The phenomenon of atherosclerosis reversal and regression:
lessons from animal models. Exp Mol Pathol 2017;102:138-45.
65. Orekhov AN. Direct anti-atherosclerotic therapy; development of natural anti-atherosclerotic drugs preventing cellular cholesterol
retention. Curr Pharm Des 2013;19:5909-28.
66. Zakiev ER, Nikiforov NG, Orekhov AN. Cell-based models for development of antiatherosclerotic therapies. Biomed Res Int
2017;2017:5198723.
67. Orekhov AN, Tertov VV, Novikov ID, Krushinsky AV, Andreeva ER, et al. Lipids in cells of atherosclerotic and uninvolved human